Symbol="CYCN"
AssetType="Common Stock"
Name="Cyclerion Therapeutics Inc"
Description="Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery, development, and commercialization of drugs for serious diseases of the central nervous system (CNS). The company is headquartered in Cambridge, Massachusetts."
CIK="1755237"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="301 BINNEY STREET, CAMBRIDGE, MA, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="6741800"
EBITDA="-38396752"
PERatio="None"
PEGRatio="None"
BookValue="1.804"
DividendPerShare="0"
DividendYield="0"
EPS="-16.7"
RevenuePerShareTTM="0.42"
ProfitMargin="0"
OperatingMarginTTM="-42.05"
ReturnOnAssetsTTM="-0.829"
ReturnOnEquityTTM="-1.858"
RevenueTTM="914000"
GrossProfitTTM="-29749000"
DilutedEPSTTM="-16.7"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0.141"
AnalystTargetPrice="4"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="17.43"
PriceToBookRatio="1.711"
EVToRevenue="0.517"
EVToEBITDA="0.529"
Beta="1.888"
num_52WeekHigh="25"
num_52WeekLow="2.767"
num_50DayMovingAverage="4.183"
num_200DayMovingAverage="9.16"
SharesOutstanding="2407800"
DividendDate="None"
ExDividendDate="None"
symbol="CYCN"
open="2.82"
high="2.92"
low="2.80"
price="2.80"
volume="7460.00"
latest_trading_day="2023-07-28"
previous_close="2.87"
change="-0.07"
change_percent="-2.4390%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="88"
trend_strength="Absent or Weak Trend"
buying_signal="Strong Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="12"
Volume_recent_avg="198509"
Change_recent_avg="-0.01"
Delta_recent_avg="0.21"
Variance_recent_avg="0.1"
Change_ratio_recent_avg="-1.2"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="12"
Aroon_momentum_negative="88"
image_negative_thumbnail_id_1="1152"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0185.jpeg"
image_negative_thumbnail_id_2="119"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0057.jpeg"
image_neutral_thumbnail_id_1="523"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0076.jpeg"
image_neutral_thumbnail_id_2="545"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0054.jpeg"
image_positive_thumbnail_id_1="688"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0020.jpeg"
image_positive_thumbnail_id_2="639"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0069.jpeg"
image_professor_thumbnail_id_1="1172"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0006.jpeg"
image_professor_thumbnail_id_2="1182"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0016.jpeg"
